Table 1.

Demographic and clinical characteristics of aGVHD response groups

	No aGVHD (n = 437)	SS aGVHD (n = 99)	SD aGVHD (n = 96)	Steroid-refractory aGVHD (n = 152)
Female sex, n (%)	181 (41%)	36 (36%)	37 (39%)	56 (37%)
Age at transplantation, y
0-17	113 (26%)	15 (15%)	4 (4%)	15 (10%)
≥18	324(74%)	84 (85%)	92 (96%)	137 (90%)
Diagnosis category
Acute leukemia	312 (72%)	75 (75%)	63 (65%)	99 (65%)
MDS	52 (12%)	9 (9%)	10 (10%)	22 (14%)
Multiple myeloma	9 (2%)	4 (4%)	7 (7%)	7 (5%)
Lymphoma	58 (13%)	10 (10%)	14 (15%)	14 (9%)
Myeloproliferative disorder/other	6 (1%)	1 (1%)	2 (2%)	10 (7%)
Donor
Haploidentical	35 (8%)	1 (1%)	3 (3%)	4 (3%)
Matched sibling	168 (38%)	30 (30%)	33 (34%)	44 (29%)
UCB	214 (49%)	60 (61%)	50 (52%)	75 (49%)
URD	20 (5%)	8 (8%)	10 (10%)	29 (19%)
Conditioning intensity
MAC	194 (44%)	45 (45%)	44 (46%)	61 (40%)
RIC	243 (56%)	54 (55%)	52 (54%)	91 (60%)
GVHD prophylaxis
CsA/MTX	77 (18%)	20 (20%)	12 (12%)	19 (12%)
CsA/MMF	246 (56%)	66 (67%)	78 (81%)	105 (69%)
Sirolimus/MMF	55 (13%)	11 (11%)	1 (1%)	12 (8%)
Other	59 (14%)	2 (2%)	5 (5%)	16 (11%)
DRI
Very high/high risk	111 (25%)	17 (17%)	11 (11%)	26 (17%)
Intermediate risk	283 (65%)	68 (69%)	71 (74%)	107 (70%)
Low risk	43 (10%)	14 (14%)	14 (15%)	19 (12%)
HCT comorbidity index
0	201 (46%)	48 (48%)	47 (49%)	68 (45%)
1-2	130 (30%)	31 (31%)	24 (25%)	34 (22%)
3+	106 (24%)	20 (20%)	25 (26%)	50 (33%)
Karnofsky performance status
<90	78 (18%)	13 (13%)	10 (10%)	28 (18%)
≥90	359 (82%)	86 (87%)	86 (90%)	124 (82%)
MN GVHD risk
High risk		16 (16%)	19 (20%)	40 (26%)
Standard risk		83 (84%)	77 (80%)	112 (74%)

MDS, myelodysplastic syndrome; MN, Minnesota; MTX, methotrexate.